Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 20.16%93.46B | 54.05%31.13B | 26.80%22.58B | 19.95%23.37B | -44.63%11.23B | 28.20%77.78B | 20.64%20.2B | 1.22%17.81B | 41.42%19.48B | 61.60%20.28B |
Operating revenue | 20.16%93.46B | 54.05%31.13B | 26.80%22.58B | 19.95%23.37B | -44.63%11.23B | 28.20%77.78B | 20.64%20.2B | 1.22%17.81B | 41.42%19.48B | 61.60%20.28B |
Cost of revenue | 25.78%70.51B | 59.06%23.95B | 34.96%17.45B | 19.18%16.85B | -12.01%12.26B | 19.56%56.06B | 19.01%15.06B | 0.72%12.93B | 27.75%14.14B | 34.86%13.93B |
Gross profit | 5.65%22.94B | 39.39%7.17B | 5.20%5.13B | 21.97%6.52B | -35.08%4.12B | 57.60%21.72B | 25.68%5.14B | 2.55%4.88B | 97.28%5.34B | 186.06%6.35B |
Operating expense | 18.44%19.03B | 34.32%6.04B | 11.18%4.41B | 5.58%4.47B | 21.90%4.11B | 16.44%16.07B | 51.74%4.5B | 11.87%3.96B | 1.91%4.23B | 7.46%3.37B |
Selling and administrative expenses | 12.45%16.74B | 12.21%5.31B | 9.79%3.83B | 5.50%3.96B | 24.97%3.64B | 24.92%14.89B | 51.29%4.73B | 15.10%3.49B | 11.36%3.75B | 22.03%2.92B |
-Selling and marketing expense | 16.97%7.78B | 12.67%2.34B | 18.60%1.93B | 14.08%1.88B | 25.50%1.62B | 45.50%6.65B | 56.09%2.08B | 29.60%1.63B | 47.07%1.65B | 50.27%1.29B |
-General and administrative expense | 8.79%8.96B | 11.84%2.96B | 2.07%1.9B | -1.23%2.08B | 24.55%2.02B | 12.11%8.24B | 47.73%2.65B | 4.83%1.86B | -6.43%2.11B | 6.12%1.62B |
Research and development costs | 17.90%2.28B | 38.43%738.68M | 21.48%572.93M | 6.26%504.51M | 2.31%467.3M | -23.92%1.94B | 4.91%533.62M | -7.40%471.63M | -39.02%474.79M | -39.02%456.74M |
Other operating expenses | ---- | ---- | ---- | ---- | ---- | -14.02%-762.07M | ---- | ---- | ---- | ---- |
Operating profit | -30.71%3.92B | 74.77%1.13B | -20.68%726.96M | 84.21%2.05B | -99.60%11.85M | 34,405.74%5.65B | -42.85%644.39M | -24.61%916.46M | 177.25%1.11B | 424.41%2.98B |
Net non-operating interest income expense | -0.25%1.26B | -9.15%283.42M | -11.07%310.49M | 5.27%356.58M | 17.53%309.68M | 69.92%1.26B | 22.19%311.96M | 62.61%349.14M | 111.58%338.74M | 132.44%263.49M |
Non-operating interest income | -2.43%1.26B | -16.67%283.42M | -11.07%310.49M | 5.27%356.58M | 17.53%309.68M | 67.92%1.29B | 21.07%340.12M | 62.61%349.14M | 111.58%338.74M | 132.44%263.49M |
Non-operating interest expense | ---- | ---- | ---- | ---- | ---- | 31.75%19.09M | ---- | ---- | ---- | ---- |
Total other finance cost | ---- | ---- | ---- | ---- | ---- | -18.48%9.07M | ---- | ---- | ---- | ---- |
Other net income (expense) | 74.92%1.69B | 203.05%200.59M | 56.21%634.08M | 183.38%341.27M | -18.70%517.42M | 322.70%968.11M | 48.80%-194.66M | 247.77%405.93M | 178.84%120.43M | 70.65%636.42M |
Gain on sale of security | -70.25%278.12M | -84.80%118.53M | 58.25%154.33M | 173.66%15.25M | -112.82%-9.98M | 498.33%934.7M | 7.23%780M | 151.19%97.52M | 92.34%-20.7M | 170.51%77.87M |
Earnings from equity interest | 12.02%10.19M | 133.89%6.14M | -38.97%7.78M | -96.01%351K | -172.06%-4.09M | -79.60%9.1M | -26,175.36%-18.13M | -3.29%12.75M | 130.45%8.81M | -90.61%5.67M |
Special income (charges) | -20.85%-160.98M | -51.11%-116.15M | 97.28%-388K | 4.23%-38.3M | -192.85%-6.15M | 81.98%-133.22M | 55.09%-76.86M | 94.08%-14.27M | 86.65%-39.99M | 92.43%-2.1M |
-Less:Impairment of capital assets | 62.26%151.58M | 107.75%115.18M | --0 | 11.05%36.4M | ---- | -36.90%93.42M | -22.80%55.44M | --5.2M | -57.01%32.78M | ---- |
-Write off | -75.98%9.41M | -95.33%971K | -95.72%388K | -73.63%1.9M | 192.85%6.15M | -93.38%39.17M | -79.21%20.79M | -96.24%9.06M | -96.77%7.21M | -92.43%2.1M |
-Gain on sale of property,plant,equipment | ---- | ---- | ---- | ---- | ---- | -196.32%-629K | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 894.14%1.57B | 121.83%192.07M | 52.42%472.36M | 111.23%363.97M | -3.12%537.64M | 51.82%157.53M | 6.06%-879.67M | 115.99%309.91M | -61.36%172.31M | 23.14%554.97M |
Income before tax | -12.86%6.87B | 111.40%1.61B | 0.00%1.67B | 74.80%2.75B | -78.37%838.95M | 2,597.32%7.88B | -24.03%761.7M | 44.63%1.67B | 209.65%1.57B | 998.31%3.88B |
Income tax | 39.99%2.79B | 1,027.30%1.03B | 0.38%503.13M | 210.56%848.96M | -63.94%406.83M | 18.04%1.99B | -85.47%91.63M | 14.04%501.24M | -36.62%273.37M | 500.26%1.13B |
Net income | -30.76%4.08B | -13.85%577.25M | -0.16%1.17B | 46.24%1.9B | -84.29%432.12M | 521.50%5.89B | 80.17%670.06M | 63.41%1.17B | 169.65%1.3B | 543.77%2.75B |
Net income continuous Operations | -30.76%4.08B | -13.85%577.25M | -0.16%1.17B | 46.24%1.9B | -84.29%432.12M | 521.50%5.89B | 80.17%670.06M | 63.41%1.17B | 169.65%1.3B | 543.77%2.75B |
Minority interest income | 108.15%13.28M | 1,484.28%7.26M | -121.77%-2.67M | 190.41%8.34M | -88.01%348K | 156.91%6.38M | 458K | 12.25M | -453.97%-9.23M | 275.35%2.9M |
Net income attributable to the parent company | -30.91%4.06B | -14.88%569.99M | 1.13%1.17B | 44.57%1.89B | -84.28%431.77M | 524.45%5.88B | 74.78%669.61M | 61.70%1.16B | 170.05%1.31B | 544.49%2.75B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -30.91%4.06B | -14.88%569.99M | 1.13%1.17B | 44.57%1.89B | -84.28%431.77M | 524.45%5.88B | 74.78%669.61M | 61.70%1.16B | 170.05%1.31B | 544.49%2.75B |
Basic earnings per share | -28.74%3.57 | -10.53%0.51 | 6.06%1.05 | 51.35%1.68 | -83.12%0.39 | 528.21%5.01 | 72.73%0.57 | 65.00%0.99 | 171.15%1.11 | 552.94%2.31 |
Diluted earnings per share | -29.45%3.45 | -15.79%0.48 | 3.13%0.99 | 50.00%1.62 | -84.00%0.36 | 517.95%4.89 | 90.00%0.57 | 60.00%0.96 | 169.23%1.08 | 541.18%2.25 |
Dividend per share | 2.4978 | 0 | 0 | 0 | 2.4978 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |